X
API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
Other Certificates
Other Suppliers
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
https://www.reuters.com/business/healthcare-pharmaceuticals/bayers-patent-blood-thinner-xarelto-invalid-uk-court-rules-2024-04-12/
https://www.prnewswire.com/news-releases/findings-presented-at-acc24-showed-xarelto-rivaroxaban-reduced-the-risk-of-clinically-significant-bleeding-and-net-adverse-clinical-events-or-rehospitalization-302109625.html
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208220
https://www.ema.europa.eu/en/documents/overview/rivaroxaban-mylan-epar-medicine-overview_en.pdf
https://endpts.com/anthos-blood-thinner-cuts-the-risk-of-bleeding-amid-race-to-develop-safer-anticoagulants/
https://www.jnj.com/new-voyager-pad-analyses-reinforce-benefit-of-xarelto-rivaroxaban-plus-aspirin-across-high-risk-and-complex-patient-populations-with-peripheral-artery-disease-pad
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208557
https://www.fiercebiotech.com/biotech/blackstones-250m-bet-beats-xarelto-phase-2-bleeding-trial-making-case-anthos-ex-novartis
https://www.reuters.com/business/healthcare-pharmaceuticals/us-name-first-10-drugs-medicare-price-negotiation-2023-08-29/
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208561
https://www.zent2u.com/news/convenient-treatment-option-thromboembolic-events
https://www.prnewswire.com/news-releases/new-voyager-pad-analysis-confirms-consistent-benefit-of-xarelto-rivaroxaban-plus-aspirin-following-lower-extremity-revascularization-ler-301762498.html
https://www.pharmacytimes.com/view/study-confirms-benefit-of-rivaroxaban-for-secondary-prevention-of-venous-thromboembolism-in-patients-with-cancer
https://www.digitaljournal.com/pr/alfa-chemistry-enriches-api-supply-by-adding-lenalidomide-parecoxib-sodium-and-rivaroxaban
https://www.escardio.org/The-ESC/Press-Office/Press-releases/COVID-19-inpatients-do-not-gain-from-aspirin-and-rivaroxaban-combined-or-colchicine-alone
https://www.pharmacompass.com/pdf/news/fda-confirms-paragraph-iv-patent-litigation-for-xarelto-rivaroxaban-1661948882.pdf
https://www.fiercepharma.com/pharma/bayers-xarelto-squeeze-rolls-china-cancer-newcomer-nubeqa-continues-pick-steam
https://tiefenbachergroup.com/2022/07/15/global-market-launch-tiefenbacher-pharmaceuticals-expands-the-launch-of-the-anticoagulant-medicine-rivaroxaban-to-central-america-and-further-international-markets/
https://www.fiercepharma.com/pharma/eliquis-will-return-cvs-formulary-after-wave-criticism-cites-lower-net-cost-negotiations-bms
https://www.prnewswire.com/news-releases/new-data-from-two-large-studies-reinforce-effectiveness-of-dual-pathway-inhibition-dpi-with-xarelto-rivaroxaban-plus-aspirin-in-patients-with-coronary-artery-disease-cad-andor-peripheral-artery-disease-pad-301552796.html
https://www.fiercepharma.com/pharma/bayers-pharma-sector-feels-effects-xarelto-generics-china
https://www.prnewswire.com/news-releases/data-from-new-voyager-pad-analyses-at-acc22-reinforce-benefit-of-xarelto-rivaroxaban-plus-aspirin-in-patients-with-peripheral-artery-disease-pad-and-various-co-morbid-conditions-301515529.html
https://www.reuters.com/business/healthcare-pharmaceuticals/bayer-gets-fda-fast-track-status-next-generation-blood-thinner-2022-02-10/
https://www.prnewswire.com/news-releases/fda-approves-two-new-indications-for-xarelto-rivaroxaban-to-help-prevent-and-treat-blood-clots-in-pediatric-patients-301448701.html
https://www.ariva.de/news/bayer-to-present-data-from-voyager-pad-xarelto-and-9850734
https://www.reuters.com/business/healthcare-pharmaceuticals/bayer-wins-eu-patent-extension-best-selling-xarelto-drug-2021-10-29/
https://www.globenewswire.com/news-release/2021/10/04/2307727/0/en/New-data-in-the-European-Heart-Journal-show-ciraparantag-reverses-the-anticoagulant-activity-of-apixaban-and-rivaroxaban-in-elderly-patients.html
https://www.globenewswire.com/news-release/2021/10/04/2307727/0/en/New-data-in-the-European-Heart-Journal-show-ciraparantag-reverses-the-anticoagulant-activity-of-apixaban-and-rivaroxaban-in-elderly-patients.html
https://www.clinicaltrialsarena.com/news/janssen-xarelto-blood-clots/
https://www.fiercepharma.com/pharma/j-j-bayer-s-xarelto-scores-fda-nod-post-surgery-artery-disease-patients-as-pair-try-to-catch
https://endpts.com/immunocores-bispecific-lands-speedy-review-with-fda-ema-low-profile-gene-therapy-player-grabs-30m/
https://www.prnewswire.com/news-releases/fda-approves-expanded-peripheral-artery-disease-pad-indication-for-xarelto-rivaroxaban-plus-aspirin-to-include-patients-after-lower-extremity-revascularization-ler-due-to-symptomatic-pad-301361537.html
https://www.fiercepharma.com/pharma-asia/astrazeneca-s-pulmicort-bayer-s-xarelto-among-big-losers-china-s-largest-price-cut
https://www.prnewswire.com/news-releases/janssen-submits-new-drug-application-to-us-fda-for-xarelto-rivaroxaban-to-help-prevent-and-treat-blood-clots-in-pediatric-patients-301318306.html
https://www.fiercepharma.com/pharma/acc-2021-j-j-bayer-pad-case-for-xarelto-post-surgery-artery-disease-patients
https://www.prnewswire.com/news-releases/late-breaking-data-at-acc21-show-xarelto-rivaroxaban-plus-aspirin-significantly-reduced-total-ischemic-events-in-peripheral-artery-disease-pad-patients-after-lower-extremity-revascularization-301292138.html
https://www.fiercepharma.com/pharma/bayer-gives-first-look-at-pharma-s-post-xarelto-eylea-life-and-it-looks-better-than-expected
http://www.pharmatimes.com/news/bayers_xarelto_approved_in_the_uk_1362524
https://www.fiercepharma.com/pharma/bayer-pharma-chief-admits-to-unfillable-revenue-gap-despite-potential-blockbuster-launches
https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/natco-pharma-launches-anti-blood-clot-medication-rivaroxaban-in-india/articleshow/79779503.cms
https://newsroom.heart.org/news/rivaroxaban-may-be-as-effective-as-warfarin-for-bioprosthetic-mitral-valves-af#:~:text=14%2C%202020%20%E2%80%94%20The%20primary%20results,according%20to%20late%2Dbreaking%20research
https://www.prnewswire.com/news-releases/new-xarelto-rivaroxaban-peripheral-artery-disease-pad-data-from-explorer-clinical-research-program-to-be-unveiled-at-american-heart-association-aha-scientific-sessions-2020-301168370.html
https://www.jnj.com/janssen-submits-application-to-u-s-fda-for-new-indication-to-expand-use-of-xarelto-rivaroxaban-in-patients-with-peripheral-artery-disease
https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-14-17-september-2020
Market Place
Share 
